Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Steroid bill excludes AERs

This article was originally published in The Tan Sheet

Executive Summary

Senate Judiciary Committee approves the Anabolic Steroid Control Act (S 2195) Sept. 30 without language establishing mandatory adverse event reporting for supplements urged by Sen. Richard Durbin (D-Ill.). Durbin and committee Chair Orrin Hatch (R-Utah) agreed in June to work together to develop AER legislation with input from industry and other stakeholders. Hatch noted at the time the steroid bill could serve as a vehicle for AER language (1"The Tan Sheet" June 28, 2004, p. 3). According to staffers, the senators have worked out language which is likely to appear in a separate bill. Steroid control bill, which would ban androstenedione and a number of other steroid precursors, retains a controversial exemption for dehydroepiandrosterone (DHEA), along with estrogens and corticosteroids. The House passed a version of the bill in June (2"The Tan Sheet" June 7, 2004, p. 13)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS097365

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel